Our results demonstrated that combining QRHXF with anti-PD-1 therapy reversed the depletion of CD8+T cells and downregulated chemokine ligands and receptors, thereby alleviating TME-associated immunosuppression in NSCLC and enhancing the efficacy of immunotherapy. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.